Sight Sciences (NASDAQ:SGHT) CFO Sells $17,317.92 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 2,616 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $6.62, for a total transaction of $17,317.92. Following the sale, the chief financial officer directly owned 151,230 shares of the company’s stock, valued at $1,001,142.60. The trade was a 1.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

James Rodberg also recently made the following trade(s):

• On Tuesday, January 6th, James Rodberg sold 594 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total transaction of $4,443.12.
• On Monday, January 5th, James Rodberg sold 4,405 shares of Sight Sciences stock. The shares were sold at an average price of $7.82, for a total transaction of $34,447.10.

Sight Sciences Stock Performance

NASDAQ:SGHT opened at $6.02 on Friday. Sight Sciences, Inc. has a 52 week low of $2.03 and a 52 week high of $9.24. The company has a quick ratio of 8.93, a current ratio of 9.60 and a debt-to-equity ratio of 0.62. The company has a market cap of $318.28 million, a price-to-earnings ratio of -6.69 and a beta of 2.42. The company has a fifty day simple moving average of $7.75 and a two-hundred day simple moving average of $5.36.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.10. Sight Sciences had a negative return on equity of 61.59% and a negative net margin of 60.63%.The firm had revenue of $19.91 million for the quarter, compared to the consensus estimate of $17.74 million. As a group, equities analysts anticipate that Sight Sciences, Inc. will post -0.99 earnings per share for the current fiscal year.

Institutional Trading of Sight Sciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Americana Partners LLC raised its stake in Sight Sciences by 42.4% during the 3rd quarter. Americana Partners LLC now owns 1,229,819 shares of the company’s stock valued at $4,231,000 after purchasing an additional 365,901 shares during the last quarter. Palumbo Wealth Management LLC bought a new stake in Sight Sciences in the 2nd quarter valued at $328,000. B Group Inc. raised its stake in shares of Sight Sciences by 11.6% in the 2nd quarter. B Group Inc. now owns 930,000 shares of the company’s stock valued at $3,841,000 after buying an additional 96,400 shares in the last quarter. Bank of Montreal Can bought a new position in shares of Sight Sciences during the 2nd quarter worth about $49,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in Sight Sciences by 38.9% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,888 shares of the company’s stock valued at $66,000 after acquiring an additional 4,453 shares during the period. Institutional investors and hedge funds own 55.51% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Citigroup upped their price target on shares of Sight Sciences from $5.50 to $9.10 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. UBS Group upped their target price on shares of Sight Sciences from $7.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, December 23rd. Lake Street Capital boosted their price objective on Sight Sciences from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sight Sciences in a research note on Monday, December 29th. Finally, Raymond James Financial set a $9.00 price target on Sight Sciences in a research report on Monday, January 5th. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $8.30.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.